Jessell Owens, MD
Orthopaedic Surgery · Sparks, NVNPI 1629459938
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $7,057 of the $10,873 with a category attached, or 64.9%. 12 manufacturers reported payments, led by Stryker at 55.7% of the total. Reporting peaked in 2022 at $4,269 and has fallen 99.1% since, to $38 in 2025.
Across 78 payments — averaging $139.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$6K
- Zimmer Biomet$2K
- Omnilife Science, Inc$932
- Johnson & Johnson$535
- Medical Device Business Services, Inc.$456
- Smith+Nephew$397
- plus $240 from 6 others
What the payments were for
- Travel & lodging$7,05765%
- Food & beverage$3,37431%
- Education$4424%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 24 | $6,059 |
| Zimmer Biomet | 18 | $2,254 |
| Omnilife Science, Inc | 7 | $932 |
| Johnson & Johnson | 8 | $535 |
| Medical Device Business Services, Inc. | 8 | $456 |
| Smith+Nephew | 6 | $397 |
| Restor3d, Inc. | 1 | $102 |
| Next Science LLC | 1 | $42 |
| AbbVie | 2 | $41 |
| SK Life Science, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Heron Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$5,653
- INSIGNIA$866
- Persona$726
- RESTORATION$704
- Oxford-Knees$467
- ROSA$419
- mymobility Platform$419
- REAL INTELLIGENCE$258
- TRIATHLON$155
How this compares
$10,873 in reported general payments places this provider in the 65th percentile of 135 orthopaedic surgery providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 24 | $568 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 34 | $351 |
| Diclofenac Sodium | 22 | $284 |
| Meloxicam | 78 | $138 |
| Gabapentin | 11 | $124 |
| Amoxicillin | 94 | $115 |
| Methylprednisolone | 23 | $113 |
| Oxycodone Hcl | 14 | $82 |
| Tramadol Hcl | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Sparks
- Mark BarryLas Vegas$9.5M
- Erik KubiakLas Vegas$7.8M
- Russell NevinsLas Vegas$1.5M
- Vladimir SinkovLas Vegas$434K
- Robert TaitHenderson$365K
- Ronald HillockLas Vegas$275K
- Galen KamLas Vegas$270K
- Michael DaubsLas Vegas$215K
- Hilary MalcarneyReno$189K
- John BaldaufLas Vegas$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.